An anaesthesia gas could be the next big thing in treating Alzheimer’s disease.
- Director of Research, Associate Professor in Therapeutics, University of Bradford
Un nuevo estudio demuestra que el lecanemab retrasa la progresión de la enfermedad en su fase inicial. Pero los efectos secundarios son relevantes.
Lecanemab slows progression of early-stage Alzheimer’s disease in some, new study shows. But the ‘adverse events’ are significant.
Experimental drugs gantenerumab has failed phase 3 clinical trials. Here’s what that means for the future of the amyloid hypothesis.
Contact Ritchie for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
- Location: Bradford
- Website
- X (formerly Twitter): @RWilliamsonLab
- Article Feed
- ORCID
- Joined
